ALLMedicine™ Pediatric Vaccines Center

Mar 8th, 2023 - Switching a vaccine for another on a pediatric national immunization program is often done for the betterment of society. However, if poorly implemented, switching vaccines could result in suboptimal transitions with negative effects. A systematic...

Feb 2nd, 2023 - For toddlers, the duration of each participant's participation in the study will be approximately 6 months for subjects enrolled in Groups 1, 2, 3, and 4. For infants, the duration of each participant's participation in the study will be approxima...

Jan 10th, 2023 - Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines (PCVs) confer protection against PD caused by most vaccine serotypes, but non-vaccin...

Jan 5th, 2023 - Study duration per participant is approximately 1 year in Group 1 and Group 2, and 10 months in Group 3 and Group 4. This duration includes a safety follow-up contact at 6 months after the last vaccination.

Jan 5th, 2023 - Primary objective is to demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following the administration of a 3-dose series of MenACYW conjugate vaccine compared to a 3-dose series of a licensed...

Feb 2nd, 2023 - For toddlers, the duration of each participant's participation in the study will be approximately 6 months for subjects enrolled in Groups 1, 2, 3, and 4. For infants, the duration of each participant's participation in the study will be approxima...

Jan 5th, 2023 - Study duration per participant is approximately 1 year in Group 1 and Group 2, and 10 months in Group 3 and Group 4. This duration includes a safety follow-up contact at 6 months after the last vaccination.

Jan 5th, 2023 - Primary objective is to demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following the administration of a 3-dose series of MenACYW conjugate vaccine compared to a 3-dose series of a licensed...

Jan 4th, 2023 - Study duration per participant is approximately 16 months, which includes a safety follow-up contact at 6 months after the final vaccination

Jan 4th, 2023 - The duration of each subject's participation in the trial will be approximately 16 to 19 months (Subgroup 1a) and 19 to 22 months (Subgroup 1b and Group 2), which includes a safety follow up contact at 6 months after the last vaccinations.

Sep 12th, 2022 - Introduction ICYMI articles featuring 9 important developments of the past year – and COVID is still here By Christopher J. Harrison, MD Table of contents Antibiotics use and vaccine antibody levels Commentary Emerging tick-borne pathogen has spre.

Aug 31st, 2022 - The confirmed dates for the shots' delivery comes a week after President Andres Manuel Lopez Obrador said he would complain to the United Nations about the delayed shipment of vaccines the government had requested. Of the 10 million doses en route...

Mar 23rd, 2022 - (Adds doctor comment, details on side effects) March 23 (Reuters) - Moderna Inc said on Wednesday it will ask regulators to authorize its COVID-19 vaccine for children younger than 6 years old based on data showing it generated a similar immune re...

Dec 2nd, 2021 - BETHESDA, Md. -- President Biden on Thursday announced several steps his administration is taking to prepare the country for an increase in COVID-19 cases during the winter as well as the possible spread of the Omicron variant. "Experts say COVID-...

Oct 6th, 2021 - The coronavirus disease 2019 (COVID-19) has the potential to erode vaccine and treatment trust, explained Anna Giuliano, PhD, who added that the work researchers are doing to build resiliencies back into vaccine programs and develop simpler therap...